Press Releases
Relmada Therapeutics Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market
Relmada Therapeutics Announces Completion of Dosing with REL-1017 in Phase 2 Study of Individuals with Treatment Resistant Depression
Relmada Therapeutics to Present at LD Micro Invitational Conference in Los Angeles
Relmada Therapeutics Presents Development Program of REL1017 for Treatment of Depression at the 2019 American Society of Clinical Psychopharmacology Meeting
Relmada Therapeutics Announces Publication of REL1017 Phase 1 Studies Results
Gina DiGuglielmo Joins Relmada as Vice President and Head of Clinical Operations
Relmada Therapeutics to Present at Biotech Showcase 2019
Relmada Therapeutics Presents Clinical Data on Increased BDNF Plasma Levels in Subjects Treated with REL-1017
Relmada Therapeutics to Present Clinical Data on the Effect of REL-1017 on BDNF Plasma Levels
Relmada Therapeutics Provides Enrollment Update in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder
